Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

Susan Branford, Carol Wadham, Naranie Shanmuganathan, Adelina Fernandes, Nur Hezrin Shahrin, Jinghua Feng, John Toubia, Paul Wang, Chung Hoow Kok, Muneeza Maqsood, Verity Saunders, Rob King, Ming Lin, Rosalie Kenyon, Ilaria Stefania Pagani, David T Yeung, David M. Ross, Agnes S. M. Yong, Timothy P Hughes

Blood (2023) 142 (Supplement 1): 447.

https://doi.org/10.1182/blood-2023-174425

Published: 2023

Journal Articles

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Craig S Sauter, Gautam Borthakur, Luke Mountjoy, Marcello Rotta, Hongtao Liu, Hemant S. Murthy, Ming Lin, James Trager, Cornell Chang, Nishi Kothari, David Shook, Carlos Bachier

Blood (2023) 142 (Supplement 1): 2097.

https://doi.org/10.1182/blood-2023-173582

Published: 2023

Journal Articles

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Susan Branford, Naranie Shanmuganathan, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Andreas W Schreiber, Chung Hoow Kok, Verity A Saunders, Rob King, Ming Lin, Ilaria S Pagani, David T Yeung, David M Ross, Agnes S.M. Yong, Timothy Hughes

Blood (2022) 140 (Supplement 1): 3916–3917.

https://doi.org/10.1182/blood-2022-158735

Published: 2022

Journal Articles

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Naranie Shanmuganathan, David T Yeung, Carol Wadham, Nur Hezrin Shahrin, Adelina Fernandes, Jinghua Feng, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, David M Ross, Andreas W Schreiber, Timothy Hughes, Susan Branford

Blood (2022) 140 (Supplement 1): 805–806.

https://doi.org/10.1182/blood-2022-158743

Published: 2022

Journal Articles

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

Naranie Shanmuganathan, FRACP,FRCPA,MBBS, Carol Wadham, PhD, Nur Hezrin Shahrin, PhD, Daniel Thomson, PhD BSc, Jinghua Feng, PhD, Verity A Saunders, Ming Lin, Rosalie Kenyon, Rob King, Paul Wang, PhD, David M Ross, MBBS, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Andreas W Schreiber, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Susan Branford, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-136962

Published: 2020

Journal Articles

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A Sallman, MD, Adam S. Asch, MD, Monzr M. Al Malki, MD, Daniel J. Lee, MD, William B. Donnellan, MD, Guido Marcucci, MD, Suman Kambhampati, MD, Naval G. Daver, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Joanna Van Elk, Ming Lin, PhD, Jens-Peter Volkmer, MD, Chris H Takimoto, MD PhD, Mark Chao, MD PhD, Paresh Vyas, MD PhD

Blood (2019) 134 (Supplement_1): 569.

https://doi.org/10.1182/blood-2019-126271

Published: 2019

Journal Articles

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Blood (2017) 130 (Supplement 1): 4303.

https://doi.org/10.1182/blood.V130.Suppl_1.4303.4303

Published: 2017

Journal Articles

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Blood (2011) 118 (21): 2445.

https://doi.org/10.1182/blood.V118.21.2445.2445

Published: 2011

Journal Articles

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

Blood (2011) 118 (21): 3521.

https://doi.org/10.1182/blood.V118.21.3521.3521

Published: 2011

Journal Articles

GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Blood (2010) 116 (21): LBA-3.

https://doi.org/10.1182/blood.V116.21.LBA-3.LBA-3

Published: 2010

Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Blood (2010) 116 (21): 1390.

https://doi.org/10.1182/blood.V116.21.1390.1390

Published: 2010

Journal Articles

Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS).

Chadi Nabhan, MD, FACP, Michael Taylor, PharmD, PhD, Jamie Hirata, Ming Lin, Benjamin Parsons, Christopher R. Flowers, MD

Blood (2009) 114 (22): 1381.

https://doi.org/10.1182/blood.V114.22.1381.1381

Published: 2009

Journal Articles

Characteristics of Patients with Stage I Follicular Lymphoma (FL) Selected for Watchful Waiting (WW) in the US: Report from the National LymphoCare Study (NLCS).

Jonathan W. Friedberg, Elaine Wong, Michael Taylor, Ming Lin, Mohamed Darif, Hildy Dillon

Blood (2007) 110 (11): 3315.

https://doi.org/10.1182/blood.V110.11.3315.3315

Published: 2007

Journal Articles

Correlates of Treatment Intensity for Initial Management of Follicular Lymphoma (FL) in the United States: Report from the National Lymphocare Study (NLCS).

Brian K. Link, Michael D. Taylor, John M. Brooks, Elizabeth A. Chrischilles, Ming Lin, Kara Wright, Lucy Pan, Julie M. Vose

Blood (2007) 110 (11): 2612.

https://doi.org/10.1182/blood.V110.11.2612.2612

Published: 2007

Journal Articles

Patterns of Care in Follicular Lymphoma (FL): Are Minorities Being Treated Differently? Report from the National LymphoCare Study (NLCS).

Chadi Nabhan, MD, FACP, Ewelina Morawa, MD, Jacob D. Bitran, MD, FACP, Michael D. Taylor, PhD, Ming Lin, Elaine K. Wong, MD, John Hainsworth, MD

Blood (2007) 110 (11): 367.

https://doi.org/10.1182/blood.V110.11.367.367

Published: 2007

Journal Articles

The Role of Fcγ Receptor Signaling, Tissue Factor Expression and Monocyte-Platelet Cross-Talk in the Initiation of Thrombosis by Immune Complexes.

Peter Casasanto, MS, Michael P. Reilly, PhD, Ming-Lin Liu, MD, PhD, Kevin Jon Williams, MD, Steven E. McKenzie, MD, PhD

Blood (2005) 106 (11): 2167.

https://doi.org/10.1182/blood.V106.11.2167.2167

Published: 2005

NARROW

Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML

A Phase 1 Study of NKX101, a Chimeric Antigen Receptor Natural Killer (CAR-NK) Cell Therapy, with Fludarabine and Cytarabine in Patients with Acute Myeloid Leukemia

Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors

Mutated Cancer-Related Genes Detected at Diagnosis of CML and a Novel Class of Variant Associated with the Philadelphia Translocation Are Both Independent Predictors of Inferior Outcomes

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia Applicable to Patients Treated with Novel Therapies and Standard of Care

Disruption of TP53 function by Point Mutations and Deletions Is Associated with An Increased Risk of Disease Progression within Previously Treated, Relapsed Chronic Lymphocytic Leukemia Patients

Low Expression of MiR-34a in Previously Treated Chronic Lymphocytic Leukemia Patients Is Limited to Patients with a Complete Disruption of TP53 Function and Does Not Correlate with MDM2 SNP309,

GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Racial Disparities in Disease Presentation, Treatment, and Response Rates of Follicular Lymphoma (FL) in the United States (US): Report From the National LymphoCare Study (NLCS).

Characteristics of Patients with Stage I Follicular Lymphoma (FL) Selected for Watchful Waiting (WW) in the US: Report from the National LymphoCare Study (NLCS).

Correlates of Treatment Intensity for Initial Management of Follicular Lymphoma (FL) in the United States: Report from the National Lymphocare Study (NLCS).

Patterns of Care in Follicular Lymphoma (FL): Are Minorities Being Treated Differently? Report from the National LymphoCare Study (NLCS).

The Role of Fcγ Receptor Signaling, Tissue Factor Expression and Monocyte-Platelet Cross-Talk in the Initiation of Thrombosis by Immune Complexes.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only